Zilliz Launches Milvus Ambassador Program to Empower AI Infrastructure Advocates Worldwide
Global initiative recognizes passionate individuals building the future of AI-powered vector search through open-source vector database technology
SAN FRANCISCO, June 18, 2025 /PRNewswire/ -- Zilliz, the company behind the leading open-source vector database Milvus, today announced the launch of the Milvus Ambassador Program, a global initiative designed to recognize and support passionate individuals who believe in the power of AI infrastructure and vector databases. The program creates opportunities for developers, advocates, and anyone who loves to share knowledge, inspire innovation, and make friends to contribute to the rapidly growing AI developer community.
The Milvus Ambassador Program addresses the increasing demand for vector database expertise as organizations worldwide implement AI-powered vector search and retrieval systems. By fostering a global network of contributors, the program aims to accelerate the adoption of Milvus technology while empowering developers to become thought leaders in AI infrastructure innovation.
"The future of AI-powered applications depends on robust infrastructure, and vector databases are at the heart of that infrastructure," said Chris Churilo, VP of Marketing at Zilliz. "Our ambassador program recognizes that the most impactful innovations come from passionate community members who share knowledge, mentor others, and push the boundaries of what's possible with vector database technology."
What Ambassadors Can Expect:
Visibility and recognition through Milvus's digital channels and media
Exclusive Milvus swag and badges
Skill-building opportunities in community leadership and developer advocacy
Opportunities to speak at local events, meetups, and conferences to grow regional communities (travel covered)
Join a global network of contributors dedicated to the success of Milvus
Direct collaboration with Milvus engineering teams and core contributors, providing feedback and influence on product direction
Who Should Apply?
The program is open to developers, researchers, content creators, and technical leaders with experience using Milvus vector databases and a passion for empowering others through content, events, and code. Ambassadors can contribute at their own pace, with flexible engagement levels.
Visit the Milvus Community Page to learn more about the program, or apply now by filling out the application form.
About Zilliz
Zilliz is a US-based global leader building next-generation vector database technologies, helping organizations unlock the value of unstructured data and rapidly develop AI and machine learning applications. By simplifying complex data infrastructure, Zilliz brings the power of AI within reach for enterprises, teams, and individual developers alike. Zilliz offers a fully managed, multi-cloud vector database service powered by open-source Milvus, supporting major cloud platforms such as AWS, GCP, and Azure, and is available across more than 20 countries and regions.
Headquartered in Redwood Shores, California, United States, Zilliz is backed by leading investors including Aramco's Prosperity7 Ventures, Temasek's Pavilion Capital, Hillhouse Capital, 5Y Capital, Yunqi Partners, Trustbridge Partners, and others.
SOURCE zilliz
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Why This Beaten Down Biotech Stock Might Be a Hidden Gem
In the volatile biotech industry, it is easy to overlook small-cap medical device companies, particularly those that are not yet profitable. But every now and then, a company slips under the radar despite having the ideal combination of innovation, market opportunity, and long-term strategic execution. One such company is Alphatec Holdings (ATEC), a medical technology firm specializing in advanced spine surgery solutions. Alphatec uses artificial intelligence (AI) technologies to improve surgical precision, automate signal monitoring, and provide intraoperative analytics. While it is not a pure-play AI company, AI is becoming more integrated into its platform, helping to shape the future of spine surgery. Dear Tesla Stock Fans, Mark Your Calendars for June 22 Nvidia Says Quantum Computing Is Nearing an 'Inflection Point.' Here Are the 3 Best Stocks to Buy Now to Profit. Warren Buffett Loves This Cheap Dividend Stock and So Do Company Insiders Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. With consistent revenue growth, ATEC is gradually gaining traction. Valued at a market capitalization of $1.6 billion, Alphatec stock has risen 21% year to date (YTD), outperforming the S&P 500 Index's ($SPX) gain of 2.2% YTD. Long-term investors who are willing to dig deeper may find this beaten-down growth stock to be a hidden gem. Founded in 1990, Alphatec initially focused on spinal implants and surgical instrumentation. However, it is now reimagining spine surgery as a fully integrated experience, with cutting-edge implants, navigation systems, and surgical software. The company's platform is intended to assist spine surgeons in operating with greater precision, reducing complications, shortening patient recovery times, and collecting intraoperative data for better long-term outcomes. Alphatec has achieved double-digit revenue growth lately, owing to increased surgeon adoption and new product launches. In the first quarter of 2025, total revenue increased 22% year on year to $169 million, with surgical revenue up 24%. Procedure volume is increasing as more surgeons use Alphatec's approaches. The company is quickly becoming a preferred partner for spine surgeons because of its technological capabilities. In Q1, Alphatec experienced an 18% increase in new surgeon adoption. Like most growth companies, Alphatec has yet to turn a profit despite increasing revenues. These losses are largely the result of aggressive reinvestment in growth, research and development (R&D), and surgeon support. During the quarter, the company spent $16.58 million on R&D. Adjusted gross margin reached 70.4% in the quarter. Looking at the firm's consistent revenue growth and margins, profitability may not be far away, especially if the company continues to increase procedure volumes and expand its ecosystem. Adjusted EBITDA stood at $10.5 million in the quarter, up from a $3 million loss in the year-ago quarter. At the end of Q1, Alphatec had $153.2 million in cash and cash equivalents. Management expects adjusted EBITDA of $78 million in 2025, compared to $31 million in the previous year. Analysts covering Alphatec predict that revenue will increase by 20.1% in 2025, in line with management's expectations. Revenue could rise by 18.3% in 2026, with losses gradually declining. The U.S. spine surgery market is large and growing, with a projected value of $20 billion by 2031. Chronic back pain and spinal deformities are on the rise, owing to the aging population and climbing obesity rates. While Alphatec's market share remains small, this allows the company plenty of room to grow. As demand for more precise and less invasive surgeries increases, the few companies like Alphatec with integrated, AI-capable surgical platforms may lead their industry. Of course, growing biotech stocks can be risky. Alphatec faces stiff competition from larger, established players in the medical technology industry, such as Intuitive Surgical (ISRG), Stryker (SYK), and Medtronic (MDT). Furthermore, continued losses may necessitate additional capital raises or risk share dilution. For a company in its early growth stages, however, these risks are manageable, especially given Alphatec's strong traction with both products and customers. Its sole focus on spine surgery also distinguishes the firm as an expert in its field, which is also known as a moat. Still, because Alphatec is a growing biotech company, ATEC is better suited for aggressive investors willing to hold the stock until it reaches its full potential. Last month, H.C. Wainwright analyst Sean Lee reiterated his 'Buy' rating on ATEC stock, citing the company's strong Q1 2025 performance and growth trajectory. Lee emphasized Alphatec's improved profitability, citing consecutive quarters of positive adjusted EBITDA and a decrease in cash burn. The company now expects positive cash flow by year-end, with a projected increase in adjusted EBITDA for 2025. Despite regulatory and financial risks, Lee believes Alphatec is well-positioned for long-term growth. Backed by valuation metrics like EV-to-sales and DCF analysis, Lee set a 12-month price target of $20 per share. Separately, Barclays also maintained a 'Buy' rating on ATEC with a price target of $21. Recently, Lake Street initiated coverage of ATEC stock with a price target of $18 and a 'Buy' rating. According to the analyst, Alphatec is the only major spine company fully committed to improving spinal surgery outcomes, while the rest of the industry appears disorganized or uncertain. Lake Street also predicts that Alphatec's exceptional growth rate will continue. On Wall Street, ATEC is rated a 'Strong Buy' by consensus. Of the 11 analysts covering the stock, nine have rated it a 'Strong Buy' while one analyst recommends a 'Moderate Buy' rating and one rates the stock a 'Hold.' Based on its mean price target of $18.32, Wall Street expects the stock to climb as high as 66% from current levels. Furthermore, the Street-high estimate of $22.50 per share implies potential upside of nearly 105% over the next 12 months. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Marvell is a 'very high growth' AI player: BofA analyst
Marvell Technology (MRVL) stock gains after the semiconductor tech company hosted its custom artificial intelligence (AI) chip event, showcasing its AI plans and capacity. Following the event, Bank of America (BAC) analysts lifted their price target for the stock to $90 from $80. BofA Securities senior semiconductor analyst Vivek Arya joins Market Domination to explain what drove the price target increase and why he's bullish on Marvell as an AI player. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.
Bloomberg
2 hours ago
- Bloomberg
Alibaba Cloud to Start Second Data Center in South Korea by June
Alibaba Group Holding Ltd. will open a second data center in South Korea by the end of June, accelerating its multibillion-dollar bet on artificial intelligence and cloud computing. The new facility is part of a 380 billion yuan ($52.9 billion) investment in AI and cloud infrastructure announced earlier this year, an Alibaba spokesperson said. The expansion comes in response to growing demand from South Korean businesses for cloud and AI services, the company said in a statement Thursday.
